Fenimore Asset Management Inc Checkpoint Therapeutics, Inc. Transaction History

Fenimore Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 26, 2021	SELL	$2.5 - $3.53 $68,500 - $96,722	-27,400 Closed	0 $0
Q2 2021 Jul 15, 2021	SELL	$2.36 - $3.2 $11,800 - $16,000	-5,000 Reduced 15.43%	27,400 $81,000
Q2 2019 Jul 16, 2019	SELL	$2.75 - $5.0 $75,900 - $138,000	-27,600 Reduced 46.0%	32,400 $98,000
Q1 2019 Apr 11, 2019	SELL	$2.01 - $4.01 $80,399 - $160,400	-40,000 Reduced 40.0%	60,000 $172,000
Q4 2018 Jan 11, 2019	BUY	$1.54 - $3.35 $154,000 - $335,000	100,000 New	100,000 $182,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $256M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Fenimore Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Fenimore Asset Management Inc with notifications on news.